Found: 29
Select item for more details and to access through your institution.
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01048-0
- By:
- Publication type:
- Article
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
- By:
- Publication type:
- Article
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00879-7
- By:
- Publication type:
- Article
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25469-8
- By:
- Publication type:
- Article
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22140-0
- By:
- Publication type:
- Article
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 1, p. 105, doi. 10.1111/bjh.17772
- By:
- Publication type:
- Article
Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 904, doi. 10.1111/bjh.16443
- By:
- Publication type:
- Article
Soluble B‐cell maturation antigen in multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 727, doi. 10.1002/ajh.27225
- By:
- Publication type:
- Article
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 421, doi. 10.1002/ajh.26801
- By:
- Publication type:
- Article
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. E276, doi. 10.1002/ajh.26580
- By:
- Publication type:
- Article
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m<sup>2</sup>) in combination with lenalidomide and dexamethasone.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. E193, doi. 10.1002/ajh.26150
- By:
- Publication type:
- Article
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40966-8
- By:
- Publication type:
- Article
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
- By:
- Publication type:
- Article
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 280, p. 1, doi. 10.1126/scitranslmed.3010274
- By:
- Publication type:
- Article
P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S158, doi. 10.1016/S2152-2650(21)02343-0
- By:
- Publication type:
- Article
P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S118, doi. 10.1016/S2152-2650(21)02279-5
- By:
- Publication type:
- Article
OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02100-5
- By:
- Publication type:
- Article
MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S439, doi. 10.1016/S2152-2650(21)01978-9
- By:
- Publication type:
- Article
Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01578-0
- By:
- Publication type:
- Article
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- clinical trial
Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e298, doi. 10.1016/j.clml.2019.09.490
- By:
- Publication type:
- Article
Practice Patterns with Focal Progression on Daratumumab Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e142, doi. 10.1016/j.clml.2019.09.237
- By:
- Publication type:
- Article
Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e46, doi. 10.1016/j.clml.2019.09.070
- By:
- Publication type:
- Article
Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S343, doi. 10.1016/j.clml.2017.07.164
- By:
- Publication type:
- Article
Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e82, doi. 10.1016/j.clml.2017.03.149
- By:
- Publication type:
- Article
Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e140, doi. 10.1016/j.clml.2017.03.253
- By:
- Publication type:
- Article
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00782-7
- By:
- Publication type:
- Article
Nutrition perceptions, needs and practices among patients with plasma cell disorders.
- Published in:
- 2022
- By:
- Publication type:
- Letter